Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials—impact of psychogenic non-epileptic seizures

Seizures are reported in up to 80% of low-grade gliomas (LGGs). Avila and colleagues have proposed a seizure assessment tool for brain tumor trials to quantify seizure control as a measure of antiglioma efficacy.¹ We highlight a pitfall in this assessment tool: the inability to distinguish psychogenic non-epileptic seizures (PNES) from epileptic seizures (ES).

http://ift.tt/2rwrz9e